Table 2.
The clinicopathological significance of CD44 and CD44+CD24-/low phenotype in TNBC patients.
| First author, year | Number of patients | Studied factor | Clinical significance | Cut-off for considering as positive/overexpressed | Evaluation method | The reference ID of used antibody for IHC | Number of patients with previous treatment |
|---|---|---|---|---|---|---|---|
| Diego de Mendonça Uchôa, ( 32 ) | 47 | CD44 | It is negatively associated with lymphovascular invasion. | Above 1% | IHC | MRQ-13 for CD44 | N/A |
| Francesca Collina, ( 25 ) | 143 | CD44 | It is associated with metastasis. | Above 50% | IHC | No reference ID | N/A |
| Weiyan Zou, ( 29 ) | 51 | CD44 | It is associated with higher tumor grade, large tumor size, increased lymph node metastasis, and advanced tumor stage. | N/A | IHC | ab51037 for CD44 | N/A |
| Diego de Mendonça Uchôa, ( 32 ) | 47 | CD44+CD24-/low | It is associated with increased tumor size. | For CD44, it was 1%, and for CD24, it was 33%. | IHC | MRQ-13 for CD44, and SN3b for CD24 | N/A |
| Min Hye Jang, ( 33 ) | 172 | CD44+CD24-/low | It is associated with high tumor grade. | For CD44, it was 10% and above, and for CD24, it was 10% and above. | IHC | 156-3C11 for CD44, and SN3b for CD24 | N/A |
| Shu-Jyuan Chang, 2015 | 67 | CD44+CD24-/low | No statistically significant associations were found (P-values > 0.05) | Not appropriately provided | IHC | No reference ID | N/A |
| Fang Yang, ( 26 ) | 88 | CD44+CD24-/low | No statistically significant associations were found (P-values > 0.05) | For CD44+CD24-/low, it was above 10%. | IHC | ab51037 for CD44 and ab31622 for CD24 | Eighty-two patients were on adjuvant chemotherapy. |
| Yan−Xi Liu, ( 27 ) | 140 | CD44+CD24-/low | Compared to AR+ TNBC, it is associated with higher tumor grades. | For CD44+CD24-/low, it was above 10%. | IHC | 156−3C11 for CD44, and Ab2−SN3b for CD24 | One hundred twenty-three patients were on chemotherapy. |
| Hui Wang, ( 28 ) | 145 | CD44+CD24-/low | It is positively associated with AR expression. | For CD44+CD24-/low, it was above 10%. | IHC | ab51037 for CD44, and ab31622 for CD24 | None of the patients were on targeted therapy, radiotherapy, chemotherapy, and adjuvant endocrine treatment. |
| Weiyan Zou, ( 29 ) | 51 | CD44+CD24-/low | It is associated with advanced tumor stage, large tumor size, and increased lymph node metastasis. | N/A | IHC | ab51037 for CD44 and ab31622 for CD24 | N/A |
| Nazia Riaz, ( 35 ) | 197 | CD44+CD24-/low | CD44+CD24-/low is correlated with the lack of AR expression. | N/A | IHC | M7082 for CD44, and MS1279 for CD24 | All of the patients were on standard radiotherapy/chemotherapy. |
IHC, immunohistochemistry; N/A, not available; and AR, androgen receptor.